Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benign multiple sclerosis is characterized by a stable neuroimmunologic network.

Claus G Haase1, Pedro M Faustmann

  • 1Department of Neurology, University Hospital Essen, Essen, Germany. clausgert.haase.ch@bayer-ag.de

Neuroimmunomodulation
|July 14, 2004
PubMed
Summary

Benign multiple sclerosis (MS) patients show a balanced neuroendocrine and cytokine network, potentially supported by immune-modulating therapies like corticosteroids and azathioprine, which influence disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of antipsychotic drugs on microglia-mediated neuroinflammation in schizophrenia: perspectives in an astrocyte-microglia co-culture model.

Frontiers in psychiatry·2025
Same author

Neuroglia in autoimmune encephalitis.

Handbook of clinical neurology·2025
Same author

Microglia as potential key regulators in viral-induced neuroinflammation.

Frontiers in cellular neuroscience·2024
Same author

Tiagabine and zonisamide differentially regulate the glial properties in an astrocyte-microglia co-culture model of inflammation.

Naunyn-Schmiedeberg's archives of pharmacology·2023
Same author

The potential role of astroglial GABA<sub>A</sub> receptors in autoimmune encephalitis associated with GABA<sub>A</sub> receptor antibodies and seizures.

Epilepsia open·2023
Same author

Inhibition of Microglial Activation by Amitriptyline and Doxepin in Interferon-β Pre-Treated Astrocyte-Microglia Co-Culture Model of Inflammation.

Brain sciences·2023

Area of Science:

  • Neuroimmunology
  • Endocrinology

Background:

  • Multiple sclerosis (MS) is a relapsing-remitting disease.
  • Benign MS patients (Expanded Disability Status Scale score <2) represent a distinct subgroup.
  • Cytokines and melatonin are key neuroimmunologic effectors influencing MS relapses and progression.

Purpose of the Study:

  • To evaluate clinical course and neuroimmunological parameters in benign MS.
  • To investigate the role of cytokines and melatonin in benign MS.
  • To assess the impact of azathioprine (AZA) and corticosteroids (CS) on neuroimmunological markers.

Main Methods:

  • Studied 41 female patients with benign MS.
  • Monitored clinical course and treatments over 7 years for a subgroup.
  • Evaluated neuroimmunological parameters including cytokines and melatonin during acute relapse and follow-up.

Related Experiment Videos

Main Results:

  • Benign MS course observed with mild progression (16%) over 7 years.
  • Azathioprine (AZA) treatment initially reduced melatonin levels (p=0.04) compared to untreated patients.
  • Corticosteroids (CS) during relapse increased type 2 cytokines and decreased type 1 cytokines.

Conclusions:

  • Corticosteroids (CS) act as anti-inflammatory agents during MS relapse, promoting a type 2 cytokine shift.
  • Azathioprine (AZA) subtly modulates immune function, indicated by reduced melatonin.
  • Stabilized cytokine and melatonin levels correlate with a benign MS course, suggesting a balanced network.